To interfere with increased BCL-2 or MCL-1 in BRAFi-resistant melanoma and other cancer types, alternatively, different BH3-mimetics or epigenetic drugs may be applied—the later with potential additional benefit of impacting cell cycle regulation, EMT, and CSC transdifferentiation. The gene discussed is MCL1; the disease is melanoma.